---
title: DVTs
layout: diseases
author: Corbin Cox
last-updated: 2018-7-02
created: 2018-7-02
toc: true
common: false
---

# VTE Risk Stratification

* Low: Minor surgery, fully ambulatory
  * No therapy recommended
* Moderate: Non-ortho surgery pts, acutely ill
  * Surgical Pts: UFH, LMWH, or Fondaparinux recommended up to 28d after discharge
  * Above are appropriate, but not length recommendation post-discharge
* High Risk: Orthopedic Surgery
  * Above for &ge; 10-14d post-op and up to 35d
* Use mechanical means in high bleed risk pts

# Treatment

## General Considerations

* Start parenteral and overlap w/ warfarin for at least 5d AND INR &gt; 2 for &ge; 24h
* Rivaroxaban and Apixaban do not need warfarin overlap
* Edoxaban and Dabigatran do not need warfarin overlap, but parenteral should be overlapped for 5-10d

## UFH

t<sub>1/2</sub> = 30-90min

| Condition                        | Dose                                           |
| -------------------------------- | ---------------------------------------------- |
| Initial Dose                     | 80 U/kg then 18 U/kg/hr                        |
| aPTT &lt;35s (&lt; 1.2x control) | 80 U/kg, increase rate by 4 U/kg/hr            |
| aPTT 35-45s (1.2-1.5x control)   | 40 U/kg, increase rate by 2 U/kg/hr            |
| aPTT 46-70s (1.5-2.3x control)   | No Change                                      |
| aPTT 71-90s (2.3-3x control)     | Decrease rate by 2 U/kg/hr                     |
| aPTT &gt; 90s (&gt; 3x control)  | Hold infusion x1hr, decrease rate by 3 U/kg/hr |

### Monitoring

* aPTT at baseline then q6h after dose or w/ dosage change x24h, then QD if in range
* SSx of bleeding
* SSx of HIT
* Osteoporosis
  * Doses &gt; 20k U QD for &gt; 6mo (pregnancy)
* Plt QOD x14d

### HIT

If Plts drop &gt; 50% OR to &lt; 100k consider HIT, D/C heparin, DO NOT give Plts, give bivalirudin, argatroban, fondaparinux, etc. Do not give warfarin until Plts &gt; 150k

### Heparin Reversal

**Protamin Sulfate**

| Time Elapsed | Protamin Dose (mg) / 100 U UFH |
| ------------ | ------------------------------ |
| Immediate    | 1-1.5                          |
| 30-120 min   | 0.5-0.75                       |
| &gt; 2h      | 0.25-0.375                     |

Dose is cumulative (i.e. add up dose for each time category)

**SEs**

* Hypotension / Bradycardia
  * Infuse over 1-3min NTE 50mg/10min
* Anaphylaxis
  * At risk w/ fish allergy, Surg. Hx of vasectomy, or protamine containing insulin use

## LMWH

| Drug            | Prophylactic Dose | Treatment Dose  | Note                                                         |
| --------------- | ----------------- | --------------- | ------------------------------------------------------------ |
| Enoxaparin Q12H | 30mg SubQ         | 1 mg/kg SubQ    | No Q12 dosing in CrCl &lt; 30                                |
| Enoxaparin QD   | 40mg SubQ         | 1.5 mg/kg SubQ  | 30mg or 1 mg/kg SubQ in renal failure QD for prophylactic and treatment respectively |
| Dalteparin QD   | 2.5k-5k IU SubQ   | 200 IU/kg SubQ  | Monitor anti-Xa level (0.5-1.5 4-6h after injection)         |
| Tinzaparin QD   | -                 | 1754 IU/kg SubQ |                                                              |

* Obesity and LMWH
  * NTE 144kg Enoxaparin
  * NTE 190kg Dalteparin
  * NTE 165kg Tinzaparin
* Safe in pregnancy

### Monitoring

* CBC w/ Plt
* SCr
* Fecal occult blood
* Anti-Xa Level
  * Consider in children, CKD-5, obesity, long courses, and pregnancy
  * Treatment doses expect 0.6-1 U/mL 4hr post dose in BID, our 0.1-0.3 U/mL as trough in QD dosing
  * Not recommended for routine monitoring
* **Use w/ neural anesthesia or spinal puncture can lead to spinal hematoma**

### SEs

* Bleeding
* Thrombocytopenia
* Delayed hypersensitivity

### Reversal Agent

* Protamine Sulfate
  * If w/i 8hr of last dose, 1mg per 100 IU or 1mg enoxaparin
  * If &gt; 8hr since last dose, 0.5mg per 100 IU or 1mg enoxaparin

## Fondaparinux

### Dosing

* Prophylaxis
  * 2.5mg SubQ QD
* Treatment
  * &lt; 50kg: 5mg SubQ QD
  * 50-100kg: 7.5mg SubQ QD
  * 100kg: 10mg SubQ QD

### Notes

* CI in CrCl &lt; 30
* Not for prophylaxis in body wts &lt; 50kg
* Safe in pregnancy

### Monitoring

* No routine monitoring, but can monitor Anti-Xa levels
* Bleeding

## IV Thrombin Inhibitors

| Drug        | Dose                                                 | Use                             | Note                                                         |
| ----------- | ---------------------------------------------------- | ------------------------------- | ------------------------------------------------------------ |
| Lepirudin   | 0.15 mg/kg/hr &pm; 0.4 mg/kg bolus                   | HIT                             | aPTT 1.5-2.5x normal<br />Reduce dose if CrCl &lt; 60        |
| Bivalirudin | 0.7 mg/kg then 1.75 mg/kg/hr                         | HIT<br />UFH alternative in PCI |                                                              |
| Argatroban  | 2 mcg/kg/min<br />Hepatic Impairment: 0.5 mcg/kg/min | HIT                             | Elevates INR, overlap w/ warfarin until INR &ge; 4 (then D/C argatroban) |

**Have no antidote**

## NOACs

### Approved Inidications

|             | Post-Op Prophylaxis | Non-Valvular A-Fib | DVT/PE Treatment | Secondary DVT/PE Prevention | VTE Prophylaxis |
| ----------- | ------------------- | ------------------ | ---------------- | --------------------------- | --------------- |
| Dabigatran  | Hip Only            | X                  | X                |                             |                 |
| Rivaroxaban | X                   | X                  | X                | X                           |                 |
| Apixaban    | X                   | X                  | X                | X                           |                 |
| Edoxaban    |                     | X                  | X                |                             |                 |
| Betrixaban  |                     |                    |                  |                             | X               |

### Dosing

**Post-Op Prophylaxis**

|            | Dabigatran                                                   | Rivaroxaban                                                  | Apixaban                                                     |
| ---------- | ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ |
| Dose       | Day of Surgery: 110mg x1 (1-4hr post-op)<br />Not Day of Surgery: 220mg  QD x28-35d | Hip: 10mg QD x35d<br />Knee 10mg QD x12d<br />6-10hr post-op | Hip: 2.5mg BID x35d<br />Knee 2.5mg BID x12d<br />12-24hr post-op |
| Renal Adj. | CrCl &le; 30, no evidence                                    | CrCl &le; 30, no evidence                                    | CrCl &le; 30, no evidence                                    |

**Non-Valvular A-Fib**

|            | Dabigatran           | Rivaroxaban         | Apixaban                                                     | Edoxaban                                                 |
| ---------- | -------------------- | ------------------- | ------------------------------------------------------------ | -------------------------------------------------------- |
| Dose       | 150mg BID            | 20mg QD             | 5mg BID                                                      | 60mg QD                                                  |
| Renal Adj. | CrCl 15-30: 75mg BID | CrCl 15-30: 15mg QD | 2 of the following: SCr &ge; 1.5, Age &ge; 80, or Wt &le; 60kg get 2.5mg BID <br />HD Pts: 5mg BID unless above criteria are met, then reduce | CrCl 15-50: 30mg QD<br />**Not for use if CrCl &gt; 95** |

**DVT / PE Treatment** (3mo if provoked, 3-12+mo if unprovoked)

|            | Dabigatran                                | Rivaroxaban                 | Apixaban                                  | Edoxaban                                    |
| ---------- | ----------------------------------------- | --------------------------- | ----------------------------------------- | ------------------------------------------- |
| Dose       | 150mg BID                                 | 15mg BID x3wks then 20mg QD | 10mg BID x7d then 5mg BID                 | 60mg QD                                     |
| Renal Adj. | CrCl &lt; 30: No Data                     | CrCl &lt; 30: Avoid         | CrCl &lt; 25 or SCr &gt; 2.5: No evidence | CrCl 15-50: 30mg QD<br />&le; 60kg: 30mg QD |
| Notes      | Requires 5-10d parenteral anticoagulation |                             |                                           | Requires 5-10d parenteral anticoagulation   |

**Secondary DVT / PE Prophylaxis** (May D/C after 6mo)

|                  | Rivaroxaban         | Apixaban                                  |
| ---------------- | ------------------- | ----------------------------------------- |
| Dose             | 20mg QD             | 2.5mg BID                                 |
| Renal Adjustment | CrCl &lt; 30: Avoid | CrCl &lt; 25 or SCr &gt; 2.5: No evidence |

**VTE Prophylaxis**

|                  | Betrixaban                                 |
| ---------------- | ------------------------------------------ |
| Dose             | 160mg load then 80mg QD x35-42d            |
| Renal Adjustment | CrCl 15-30: 80mg load then 40mg QD x35-42d |
| Note             | Lasts &gt; 72hr after D/C                  |

### DOAC Comparison

* Dabigatran is metabolized by glucuronidation, Betrixaban has minimal CYP, and all others are 3A4 metabolized
* All have P-GP interactions
* All have renal adjustments
* Dabigatran has higher levels of GI upset and bleeding
* Dabigatran must be left in manufacturer bottle, and is only good for 4mo

### DOAC Conversions

|                     | Dabigatran                                                   | Rivaroxaban                                                 | Apixaban                                                    | Edoxaban                                                     |
| ------------------- | ------------------------------------------------------------ | ----------------------------------------------------------- | ----------------------------------------------------------- | ------------------------------------------------------------ |
| From IV/SC Anticoag | &le; 2hr prior to next dose                                  | UFH at D/C<br />Otherwise &le; 2hr prior to next dose       | UFH at D/C<br />Otherwise at next scheduled doses           | 4h after UFH D/C<br />Otherwise at next scheduled dose       |
| To IV/SC Anticoag   | CrCl &ge; 30: 12hr after last dose<br />CrCl &lt; 30: 24hr after last dose | Next scheduled dose                                         | Next scheduled dose                                         | Next scheduled dose                                          |
| From PO Anticoag    | Warfarin: INR &lt; 2<br />Otherwise at next scheduled doses  | Warfarin: INR &lt; 3<br />Otherwise at next scheduled doses | Warfarin: INR &lt; 2<br />Otherwise at next scheduled doses | Warfarin: INR &lt; 2.5<br />Otherwise at next scheduled doses |
| To PO Anticoag      | CrCl &gt; 50: Start 3d before stopping<br />CrCl 30-50: Start 3d before stopping<br />CrCl 15-30: Start 1d before stopping | Warfarin and IV/SC bridge at next scheduled dose            | Warfarin and IV/SC bridge at next scheduled dose            | Reduce by 50%, start warfarin, and stop when INR &ge; 2      |

### CIs

* Recent GI bleeding
* Malignancy
* Recent brain, spine, or ophthalmic surgery
* Intracerebral hemorrhage
* Varices
* AV Malformations
* Concurrent use of other anticoagulants

### Reversal Agents

* Dabigatran
  * Praxbind (Idarucizumab) 5g IV (2.5g IV q15min x2)
  * Monitor aPTT at baseline, 2hr, and Q12H until normal
* Others
  * Andexanet

## Monitoring

|                         | Dabigatran                       | Rivaroxaban                   | Apixaban                     | Edoxaban                    |
| ----------------------- | -------------------------------- | ----------------------------- | ---------------------------- | --------------------------- |
| aPTT                    | At peak aPTT is 1.5-1.8x higher  | At peak aPTT is 1.5-2x higher | At peak aPTT is 1.2x higher  | At peak aPTT is 1.3x higher |
| PT                      | Insensitive                      | Insensitive                   | PT increased by 2.9x at peak | PT increased by 2x at peak  |
| TT                      | Dose-Dependent                   | Sensitive but highly variable | Insensitive                  | Insensitive                 |
| Fibrinogen              | Affected, but not dose dependent | N/A                           | N/A                          | N/A                         |
| Anti-Thrombin / Anti-Xa | Insensitive                      | Anti-Xa                       | Anti-Xa                      | Anti-Xa                     |

## Thrombolytics

### Dosing

| Drug         | Dose                                     | Consideration |
| ------------ | ---------------------------------------- | ------------- |
| tPA          | 10mg the 90mg over 2hr                   | For PE        |
| Reteplase    |                                          | Only for ACS  |
| Tenecteplase |                                          | Only for ACS  |
| Urokinase    | 4400 U/kg x10min then 4400 U/kg/hr x12hr |               |

## Therapy Disruptions for Invasive Procedures

* Stop warfarin 5d before surgery
  * Give UFH or LMWH until procedure, stoping LMWH 24hr pre-op or UFH 4-6hr pre-op
  * Resume 12-24hr after surgery